Clinical Trials Using Actinium Ac 225 Lintuzumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Actinium Ac 225 Lintuzumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

    1. Establish the MTD of Lintuzumab-Ac225 as monotherapy 2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR) 3. Confirm the safety profile of the treatment regimen 4. Estimate progression-free survival (PFS) and overall survival
    Location: 2 locations

  • Venetoclax and Lintuzumab-Ac225 in AML Patients

    The study is a multicenter, open label Phase I / II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed / refractory AML. (Phase 1 portion) 2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California